Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C21H23N3O5
CAS Number:
Molecular Weight:
397.42
MDL number:
NACRES:
NA.21
SMILES string
N(O)C(=O)c1ccc(cc1)OCCNC(=O)c2[o]c3c(c2CN(C)C)cccc3, CN(C)CC1=C(C(NCCOC2=CC=C(C(NO)=O)C=C2)=O)OC3=CC=CC=C31
InChI
1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
InChI key
MAUCONCHVWBMHK-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to pink
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
Quality Level
Related Categories
Biochem/physiol Actions
Orally bioavailable, potent and selective pan-HDAC inhibitor.
PCI-24781 (Abexinostat) is an orally bioavailable, potent, and selective pan-HDAC inhibitor that exhibits potent antitumor activities. It inhibits all Class I and Class II HDAC isoforms (Ki = 7 nM HDAC1, 19 nM HDAC2, 8.2 nM HDAC3/SMRT, 17 nM HDAC6, 280 nM HDAC8, 24 nM HDAC10) although it is reported to be a more potent inhibitor of HDACs 1 and 3 at low concentrations.
PCI-24781 (Abexinostat) is an orally bioavailable, potent, and selective pan-HDAC inhibitor that exhibits potent antitumor activities. It inhibits all Class I and Class II HDAC isoforms (Ki = 7 nM HDAC1, 19 nM HDAC2, 8.2 nM HDAC3/SMRT, 17 nM HDAC6, 280 nM HDAC8, 24 nM HDAC10) although it is reported to be a more potent inhibitor of HDACs 1 and 3 at low concentrations.
Storage Class
11 - Combustible Solids
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Joseph J Buggy et al.
Molecular cancer therapeutics, 5(5), 1309-1317 (2006-05-30)
CRA-024781 is a novel, broad spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer. CRA-024781 inhibited pure recombinant HDAC1 with
Tianshu Yang et al.
Theranostics, 11(5), 2058-2076 (2021-01-28)
Histone deacetylases (HDACs) are involved in key cellular processes and have been implicated in cancer. As such, compounds that target HDACs or drugs that target epigenetic markers may be potential candidates for cancer therapy. This study was therefore aimed to
Sofia Rivera et al.
Oncotarget, 8(34), 56210-56227 (2017-09-17)
Despite prominent role of radiotherapy in lung cancer management, there is an urgent need for strategies increasing therapeutic efficacy. Reversible epigenetic changes are promising targets for combination strategies using HDAC inhibitors (HDACi). Here we evaluated on two NSCLC cell lines
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service